Determination of Δ⁹-tetrahydrocannabinol (9THC) and 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THCCOOH) in blood and urine using gas chromatography negative ion chemical ionization mass spectrometry (GC-MS-NCl)

• Autorzy: Kała M. , Kochanowski M.

Warianty tytułu

PL

Oznaczanie Δ⁹-tetrahydrokannabinolu (9THC) i 11-nor-9-karboksy-Δ⁹-tetrahydrokannabinolu (THCCOOH) we krwi i w moczu metodą chromatografii gazowej sprzężonej ze spektrometrią mas w trybie jonizacji chemicznej i produkcji

• Języki publikacji: EN

Abstrakty

EN

A validated method for the determination of δ⁹9-1^{, were the following: limit of detection -0.25; limit of quantification- 0.5, for both analytes; linearity range-0.5-100 for 9THC and THCCOOH in blood, and 0.5-200 for THCCOOH in urine. Internal standardization was carried out using deuterated analogues of the analytes. Intra- and inter-day precision did not exceed 25% for 9THC and 7% for THCCOOH. Accuracy was confirmed using Medidrug reference materials. The method was applied to the determination of 9THC and THCCOOH in 15 blood and 2 urine samples collected from drivers suspected of driving under the influence of cannabis.}

PL

Przedstawiono zwalidowaną metodę oznaczania δ⁹⁹

Słowa kluczowe

EN

9THC; THCCOOH; GC-MS-NCI; determination

PL

9THC; THCCOOH; GC-MS-NCI; chromatografia gazowa; spektrometria masowa; jonizacja chemiczna; oznaczanie

• Wydawca: Komitet Chemii Analitycznej PAN
• Czasopismo: Chemia Analityczna
• Rocznik: 2006
• Tom: Vol. 51, No. 1
• Strony: 65--78
• Opis fizyczny: Bibliogr. 35 poz.

Twórcy

autor

Kała M.

autor

Kochanowski M.

• Institute of Forensic Research, ul. Westerplatte 9, 31-033 Cracow, Poland Fax: [phone],

Bibliografia

• 1.Baptista M.J., Monsanto P. V., Marques E.G.P., Bermejo A., Ávila S., Castanheira A.M., Margalho C.,Barroso M. and Vieira D.N., Forensic Sci. Int., 128, 66 (2002).
• 2.Baselt R.C., Disposition of Toxic Drugs and Chemicals in Man, 6th edn, Biomedical Publications,Foster City, California, 2002, p. 1004.
• 3.Chiarotti M. and Costamagna L., Forensic Sci. Int., 114, 1 (2000).
• 4.Chi Chu M.H. and Drummer O., J. Anal. Toxicol., 26, 575 (2002).
• 5.Clarke ‘s Analysis of Drugs and Poisons, 3rd edn, [Moffat A.C., Osselton M.D., Widdop B., Eds], Pharmaceutical Press, London 2004, p. 740.
• 6.D’Asaro J.A., J. Anal. Toxicol., 24, 289 (2000).
• 7.ElSohly M.A. and Salem M., in: Handbook of Analytical Separations, vol. 2 [Bogusz M., Ed.]Elsevier Science B.V., New York 2000, p. 163.
• 8.Foltz R.L., McGinnis K.M. and Chinn D.M., Biomed. Mass Spectrom., 10, 316 (1983).
• 9.Giroud Ch., Ménétrey A., Augsburger M., Buclin T., Sanchez-Mazas P. and Mangin P., Forensic Sci. Int., 123, 159 (2001).
• 10.Harvey D.J., in: Analytical methods in human toxicology, 1st edn, vol. 1, [Curry A.S., Ed.], VCH, Weinheim 1985, p. 258.
• 11.Huestis M.A., Henningfeld J.E. and Cone E.J., J. Anal. Toxicol., 16, 276 (1992).
• 12.Huestis M.A., Henningfeld J.E. and Cone E.J., J. Anal. Toxicol., 16, 283 (1992).
• 13.Huestis M.A., in: Current approaches in forensic toxicology, [Forensic Toxicologist Certification Board, Inc., Ed.] Tampa 1994, Chapter 6, p. 1.
• 14.Huestis M.A., Mitchell J.M. and Cone E.J., J. Anal. Toxicol., 20, 441 (1996).
• 15.Huestis M.A. and Cone E.J., in: Drug Abuse Handbook, [Karch S.B., Ed.], CRC Press, New York, 1998, p. 799.
• 16.Huestis M.A., Forensic Sci. Review, 14,17 (2002).
• 17.Kała M., Toxicological Analysis of Drugs of Abuse, Wydawnictwo Instytutu Ekspertyz Sądowych, Kraków 2001, p. 168 (in Polish).
• 18.Kemp P.M., Abukhalaf I.K., Manno J E , Manno B.R., Alford D.D. and Abusada G.A., J. Anal.Toxicol., 19, 285 (1995).
• 19.Kemp P.M., Abukhalaf I.K., Manno J.E, Manno B.R, Alford D.D., McWilliams M.E., Nixon F.E., Fitzgerald M.J, Reeves R.R. and Wood M.J, J. Anal. Toxicol, 19, 292 (1995).
• 20.Kintz P. and SamynN, Therapeutic Drug Monitoring, 24, 239 (2002).
• 21.Kudo K, Nagata T, Kimura K, Imamura T. and Jitsufuchi N„ J. Anal. Toxicol„ 19, 87 (1995).
• 22.Lechowicz W, Methods of the Hallucinogens Determination in Biological Fluids for Forensic Toxicology Purposes, Doctor Thesis, Jagiellonian University, Kraków 2003.
• 23.Manno J.E, Manno B.R, Kemp P.M., Dempsey A.D., Abukhalaf I.K, McWilliams M.E., Hagaman F.N. and Fitzgerald M.J, J. Anal. Toxicol, 25, 538 (2001).
• 24.Moeller M.R., Doerr G. and Warth S, J. Forensic Sci, 37, 969 (1992).
• 25.Moeller M.R, Steinmeier S. and Kraemer T, J. Chromatogr. B, 91, 713 (1998).
• 26.Moffat A.C., Science & Justice, 42, 55 (2002).
• 27.Moore Ch., Guzaldo F. and Donahue T, J. Anal. Toxicol, 25, 555 (2001).
• 28.Niedbała S.R, Kardos W.K, Fritch F.D., Kardos S, Fries T, Waga J, Robb J. and Cone J.E, J. Anal.Toxicol, 25, 289 (2001).
• 29.Pfleger K., Maurer H.H. and Weber A, Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites, 2nd edn, VCH, Weinheim 1992, p. 2911.
• 30.Steinmeyer S, Bregel D, Warth S, Kraemer T. and Moeller R, J. Chromatogr. B, 772, 239 (2002).
• 31.Sunshine I, Monograph: Marijuana (THC), Marion Laboratories Inc., New York 1985, p. 153.
• 32.Wall M.E. and Perez-Reyes M, J. Clin. Pharmacol., 21, 178 (1981).
• 33.Widdop B, Drugs of Abuse, Immunoassay Handbook, 2nd edn, The Pharmaceutical Press, London 2000, p. 781.
• 34.Wilkins D„ Haughey H, Cone E, Huestis M, Foltz R. and Rollins D, J. Anal. Toxicol., 19, 483 (1995).
• 35.Wills S, Drugs of Abuse, 1st edn, The Pharmaceutical Press, London 1997, p. 37.